

University of Aberdeen

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†

Witjes, J. Alfred; MacLennan, Steven; EAU and ESMO Guidelines Committees

Published in:
European Urology

DOI:
[10.1016/j.eururo.2019.09.035](https://doi.org/10.1016/j.eururo.2019.09.035)

Publication date:
2019

Document Version
Peer reviewed version

[Link to publication](#)

Citation for published version (APA):

Witjes, J. A., MacLennan, S., & EAU and ESMO Guidelines Committees (2019). EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. *European Urology*. <https://doi.org/10.1016/j.eururo.2019.09.035>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- ? You may not further distribute the material or use it for any profit-making activity or commercial gain
- ? You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Supplementary Table 1. Follow-up strategies after cystectomy and trimodality bladder preservation treatment according to guidelines issues by ESMO and EAU [3, 5]

		ESMO [3]	EAU [5]
Follow-up after cystectomy		<ul style="list-style-type: none"> Ab/UT/Ch every 3-6 mo for 2 yr and thereafter based on risk of recurrence Urethral wash every 3-6 mo if urethrectomy was not carried out or there is history of CIS 	<ul style="list-style-type: none"> CT every 6 mo until third year and annually thereafter In patients with multifocal disease, NMIBC, positive ureteral margin (risk of UTUC) monitoring the UUT is mandatory (>3 yr)
Follow-up after trimodality bladder preservation treatment	Cystoscopy	<ul style="list-style-type: none"> Every 3-6 mo for 2 yr 	NA
	Imaging	<ul style="list-style-type: none"> Same follow-up regimen as for cystectomy 	NA

Ab,

abdomen imaging; Ch, chest imaging; CIS, carcinoma *in situ*; CT, computed tomography; EAU, European Association of Urology; ESMO, European Society for Medical Oncology; MIBC, muscle-invasive bladder cancer; NA, not available; NCCN, National Comprehensive Cancer Network; NMIBC, non-muscle-invasive bladder cancer; UT, upper tract imaging; UTUC, upper urinary tract urothelial carcinomas; UUT, upper urinary tract

PATIENT SUMMARY

This report summarises findings from an international, multi-stakeholder project organised by EAU and ESMO. In this project, a steering committee identified areas of bladder cancer management where there is currently no good quality evidence to guide treatment decisions. From this, they developed a series of proposed statements, 71 of which achieved consensus by a large group of experts in the field of bladder cancer. It is anticipated that these statements will provide further guidance to healthcare professionals and could help to improve patient outcomes until a time when good quality evidence is available.

TAKE HOME MESSAGE

This international, multi-stakeholder project, organised by EAU and ESMO, brought together a multidisciplinary group of professional societies and world-leading experts in advanced and variant bladder cancer management to develop consensus statements on controversial issues using a Delphi survey and consensus conference approach.

TWEET

EAU-ESMO manuscript provides guidance from world-leading experts on managing advanced and variant bladder cancer